Age: 16.0
Sex: M
Vaccine: COVID19-2, FLUX
Symptoms: Lymphadenopathy, Neck pain, Off label use, Pain in extremity, Product use issue
Clinical narrative: Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps./He noticed the rash after pain started in his arm; Swollen lymphnodes; sore neck; Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps; Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps.; Location of injection for vaccine received same date: Flu shot - left  arm; Location of injection for vaccine received same date: Flu shot - left  arm; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 16-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 21Nov2022 as dose 4 (booster), single (Lot number: GJ3274) at the age of 16 years, in left arm for covid-19 immunisation; influenza vaccine (INFLUENZA VACCINE), on 21Nov2022 as dose 1, single (Batch/Lot number: unknown), in left arm. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose Number: 3, Batch/Lot No: FL3209, Location of injection: Arm Left), administration date: 10Jan2022, when the patient was 15-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 2, Batch/Lot No: EW0178, Location of injection: Arm Left), administration date: 03Jun2021, when the patient was 15-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EW0168, Location of injection: Arm Left), administration date: 13May2021, when the patient was 14-year-old, for COVID-19 immunization. The following information was reported: PRODUCT USE ISSUE (non-serious), OFF LABEL USE (non-serious) all with onset 21Nov2022, outcome "unknown" and all described as "Location of injection for vaccine received same date: Flu shot - left  arm"; VACCINATION SITE PAIN (non-serious) with onset 05Dec2022, outcome "recovering", described as "Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps"; RASH ERYTHEMATOUS (non-serious) with onset 05Dec2022, outcome "recovering", described as "Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps."; PAIN IN EXTREMITY (non-serious) with onset 05Dec2022, outcome "recovering", described as "Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps./He noticed the rash after pain started in his arm"; LYMPHADENOPATHY (non-serious) with onset 05Dec2022, outcome "recovering", described as "Swollen lymphnodes"; NECK PAIN (non-serious) with onset 05Dec2022, outcome "recovering", described as "sore neck". The events "patient got a rash on the injection point of his arm which moved down his arm with painful red bumps./he noticed the rash after pain started in his arm", "swollen lymphnodes", "sore neck", "patient got a rash on the injection point of his arm which moved down his arm with painful red bumps" and "patient got a rash on the injection point of his arm which moved down his arm with painful red bumps." required physician office visit. Therapeutic measures were taken as a result of pain in extremity, lymphadenopathy, neck pain, vaccination site pain, rash erythematous.  Additional information: Patient got a rash on the injection point of his arm which moved down his arm with painful red bumps. He also had swollen nymphonids which is creating a sore neck. He noticed the rash after pain started in his arm and is not sure how long the rash existed before the pain. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not receive any other medications within 2 weeks of vaccination. Treatment received for the adverse event: Steroid cream. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.